ArticleFrontiers in pharmacology2026
A comparative real-world analysis of finerenone and steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Finerenone and steroidal mineralocorticoid receptor antagonists (sMRAs) reduce proteinuria in chronic kidney disease (CKD), but direct comparative data from routine clinical practice remain limited. The objective of this study was to compare the effectiveness, hemodynamic effects, kidney function trajectory, and safety of finerenone versus sMRAs in patients with proteinuric CKD in routine clinical practice. Methods: This retrospective single-center cohort study included adults receiving finerenone or an sMRA between January 2021 and May 2025. Longitudinal analyses included 174 patients with at least one post-baseline assessment (finerenone, n = 96; sMRA, n = 78). Changes in proteinuria, estimated glomerular filtration rate (eGFR), blood pressure, potassium, and glycated hemoglobin were assessed using mixed-effects models. A 1:1 propensity score-matched sensitivity analysis was performed. Results: Both treatments were associated with significant proteinuria reductions at 12 months, with percentage changes of -45.63% (95% confidence interval [CI], -59.42 to -27.15) with finerenone and -44.44% (95% CI, -60.08 to -22.66) with sMRAs, without a significant between-group difference (p = 0.927). Proteinuria reduction was already significant at 1 month with sMRAs, whereas it became significant from month 6 with finerenone. Both groups showed an early eGFR decline. At month 12, the decline remained significant in the sMRA group (-4.66 mL/min/1.73 m Conclusion: In this real-world cohort, finerenone and sMRAs showed comparable antiproteinuric effectiveness. sMRAs were associated with a more pronounced blood pressure reduction, whereas finerenone showed more favorable renal profile, with lower treatment discontinuation and side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.